Dr Reddy's shares up 2% on launch of Dexmedetomidine injection in the US market

Internet Desk | Updated on September 25, 2020 Published on September 25, 2020

The pharma major Dr Reddy's Laboratories on Friday announced the launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection, in the US market.

The Precedex in 0.9% sodium chloride injection brand had sales of approximately $210 million for the most recent twelve months ending in June 2020, according to IQVIA Health data.

Snapping two-day losing streak, the company's shares gained as much as 2.2 per cent to ₹5,139 in noon trade.


Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on September 25, 2020
This article is closed for comments.
Please Email the Editor